Molecular, genetic, and therapeutic advancements in prostate cancer research: a comprehensive literature review

Satyendra Singh

doi:10.18203/2320-6012.ijrms20243745

Authors

Satyendra Singh Department of Urology, Shri P. D. Siddhivinayak Hospital, Indore, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20243745

Keywords:

Prostate cancer, Molecular mechanisms, Genetic factors, Therapeutic strategies

Abstract

Prostate cancer (PC) is distinguished by its high occurrence among men and is identified as the fifth primary cause of death, with its severity influenced by factors such as age, ethnicity, and genetics. African populations are particularly vulnerable to aggressive forms of the disease. Distinguishing low-risk from high-risk patients remains challenging owing to PC's gradual advancement. While prostate-specific antigen (PSA) detection revolutionized PC diagnosis, it led to overdiagnosis and overtreatment. Despite PSA testing modifications, its specificity remains inadequate. Breakthroughs in genetics and proteomics have introduced fresh biomarkers such as urinary PCA3, leading to the development of pioneering diagnostic assessments like the serum prostate health index (PHI) and 4K score, thereby minimizing the need for unwarranted biopsies. Standard treatments like chemotherapy and prostatectomy are augmented by novel hormone therapies offering better outcomes. Androgen deprivation and hormonal therapy show promise for addressing hormone-sensitive and castration-resistant PC.

Metrics

Metrics Loading ...

References

Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: Global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.

Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63-89.

American Cancer Society. Key statistics of prostate cancer. Available at: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed on 12 August 2024.

Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Global Oncol. 2020;6:1063-75.

Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019;123:854-60.

Liu X, Zhang Y, Duan H, Yang L, Sheng C, Fan Z, et al. Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators. Eur J Med Res. 2023;28:257.

Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom, and Canada. BMC Urol. 2019;19:19.

Force UPST. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901-13.

Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4:S3-10.

Merriel SWD, Funston G, Hamilton W. Prostate cancer in primary care. Adv Ther. 2018;35:1285-94.

Xie J, Jin C, Liu M, Sun K, Jin Z, Ding Z, et al. MRI/transrectal ultrasound fusion-guided targeted biopsy and transrectal ultrasound-guided systematic biopsy for diagnosis of prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:880336.

Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100-9.

Hoffman A, Amiel GE. The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective. Cancers (Basel). 2023;15:3402.

Farha MW, Salami SS. Biomarkers for prostate cancer detection and risk stratification. Ther Adv Urol. 2022;14:17562872221103988.

Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016;11:25.

Fernandes RC, Hickey TE, Tilley WD, Selth LA. Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer. Endocr Relat Cancer. 2019;26(5):R237-57.

Siddique HR, Nanda S, Parray A, Saleem M. Androgen receptor in human health: a potential therapeutic target. Curr Drug Targets. 2012;13(14):1907-16.

Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Men’s Health. 2019;37:288-95.

Vatapalli R, Sagar V, Rodriguez Y, Zhao JC, Unno K, Pamarthy S, et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nat Commun. 2020;11(1):4153.

Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019;37:288-95.

Takayama K, Inoue S. Transcriptional network of androgen receptor in prostate cancer progression. Int J Urol. 2013;20:756-68.

Khurana N, Sikka SC. Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer. Cancers. 2018;10:352.

Pandey P, Khan F, Seifeldin SA, Alshaghdali K, Siddiqui S, Abdelwadoud ME, et al. Targeting Wnt/β-Catenin Pathway by Flavonoids: Implication for Cancer Therapeutics. Nutrients. 2023;15:2088.

Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020;21(12):4507.

Kaplan Z, Zielske SP, Ibrahim KG, Cackowski FC. Wnt and β-Catenin Signaling in the Bone Metastasis of Prostate Cancer. Life (Basel). 2021;11(10):1099.

Parray A, Siddique HR, Nanda S, Konety BR, Saleem M. Castration-resistant prostate cancer: potential targets and therapies. Biologics. 2012;6:267-76.

Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, et al. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 2021;131(4):e135465.

Chen H, Zhou L, Wu X, Li R, Wen J, Sha J, et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed). 2016;21(5):1084-91.

Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, et al. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res. 2022;82(8):1518-33.

Rebello RJ, Pearson RB, Hannan RD, Furic L. Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes (Basel). 2017;8:71.

Bishop JL, Thaper D, Zoubeidi A. The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel). 2014;6(2):829-59.

Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ. Clinical and pathological features of hereditary prostate cancer. J Urol. 1996;155:1841-3.

Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al. Predisposing gene for early onset prostate cancer, localized on chromosome 1q42.2-2-4.3. Am J Hum Genet. 1998;62:1416-24.

Lee YC, Lee YL, Li CY. BRCA Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies. Medicina (Kaunas). 2021;57:905.

Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R. Prostate Cancer Germline Variations and Implications for Screening and Treatment. Cold Spring Harb Perspect Med. 2018;8:a030379.

Cardoso M, Maia S, Paulo P, Teixeira MR. Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis. Oncoscience. 2016;3:288-96.

Wang Y, Dai B, Ye D. CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:15708-15.

Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2016;8:8921-46.

Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21-41.

Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 2001;61:6494-9.

Silverman R. Implications for RNase L in Prostate Cancer Biology. Biochemistry. 2003;42:1805-12.

Nyquist M, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Rep. 2020;31:107669.

Wokołorczyk D, Kluźniak W, Stempa K, Rusak B, Huzarski T, Gronwald J, et al. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021;125:569-75.

Chen FZ, Zhao XK. Prostate cancer: current treatment and prevention strategies. Iran Red Crescent Med J. 2013;15:279-84.

Nguyen-Nielsen M, Borre M. Diagnostic and Therapeutic Strategies for Prostate Cancer. Semin Nuclear Med. 2016;46:484-90.

Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, et al. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells. 2020;9:2653.

Napoli A, Alfieri G, Scipione R, Leonardi A, Fierro D, Panebianco V, et al. High-intensity focused ultrasound for prostate cancer. Exp Rev Med Devices. 2020;17:427-33.

Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021;18:739-62.

Hatano K, Nonomura N. Systemic therapies for metastatic castration-resistant prostate cancer: an updated review. World J Mens Health. 2023;41:89.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378:2465-74.

Li C, Sun H, Wei W, Liu Q, Wang Y, Zhang Y, et al. Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. Cell Oncol. 2020;43:1099-116.

Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, et al. Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017;11:2643-51.

Shang T, Yu X, Han S, Yang B. Nanomedicine-based tumor photothermal therapy synergized immunotherapy. Biomater Sci. 2020;8:5241-59.

Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15:28.